Welcome to The Weekly Skin Scan where our editors keep you up-to-date on the latest news and research that could impact your practice. Browse more stories here.
In this one hour webinar, Aesthetic Authority editorial director, Randolph Waldman, M.D., will lead a panel discussion with experts in the field of dermatology and aesthetics to provide insights into managing your practice during the COVID-19 crisis. Register by clicking the link.
From the Aesthetic Authority
Dr. Randolph Waldman shares insights, realities and what’s yet to come for the private practice as a result of the Coronavirus crisis.
In combatting the pandemic, dermatologists must take critical steps to adapt operations while still providing essential patient care and preventing exposure in office settings, experts say.
Options for medical acne treatment have expanded significantly since October 2018 with the U.S. Food and Drug Administration (FDA) approval of several novel products, and the future may hold more developments.
Designating April as Rosacea Awareness Month, the National Rosacea Society aims to increase public understanding of the condition and lead individuals who may be affected to seek medical help before their condition becomes worse.
Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.
Thanks to the phase 3 study that led to dupilumab's approval in adolescent atopic dermatitis (AD), patients can now avoid off-label treatments that may pose a risk of significant long-term toxicity.
